Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).